When was Kaleido Biosciences founded?

Kaleido Biosciences was founded in 2015.

Where is Kaleido Biosciences located?

Kaleido Biosciences is headquartered in Cambridge, United States.

How many employees does Kaleido Biosciences have?

As of Sep 30, 2026, the latest employee count at Kaleido Biosciences is 9.

Is Kaleido Biosciences a funded company?

Kaleido Biosciences is a funded company, having raised a total of $165M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round.

How much is Kaleido Biosciences worth?

The last known valuation of Kaleido Biosciences was $***** as of Feb 22, 2019.

When was the latest funding round of Kaleido Biosciences?

Kaleido Biosciences' latest funding was a $***** Series C round on Jun 25, 2018, with participation from 5 investors.

Where does Kaleido Biosciences rank among its competitors?

Kaleido Biosciences ranks 979th amongst 2873 active competitors, of which 976 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Kaleido Biosciences?

Kaleido Biosciences' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Kaleido Biosciences - 2026 Company Profile, Funding, Competitors & Financials

Kaleido Biosciences is a deadpooled company based in Cambridge (United States), founded in 2015. It operates as a Developer of microbiome metabolic therapies for inflammatory conditions. Kaleido Biosciences has raised $165M in funding from investors like Fidelity Investments, Invus and Rock Springs Capital, with last known valuation of $*****. The company has 2873 active competitors, including 976 funded and 673 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of microbiome metabolic therapies for inflammatory conditions. The company is developing therapeutic products to modulate the human microbiome for the treatment of human diseases associated with microbial imbalance.

Website: kaleido.com
Social

Key Metrics

Founded Year

2015

Location

Cambridge, United States

Stage

Deadpooled

Total Funding

$165M in 3 rounds

Latest Funding Round

Series C, Jun 25, 2018, $*****

Last Known Valuation

$***** as on Feb 22, 2019

Investors

Fidelity Investments & 8 more

Ranked

979^th among 2873 active competitors

Employee Count

9 as on Sep 30, 2026

Similar Companies

Moderna & 592 more

View Kaleido Biosciences' full profile

Kaleido Biosciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Kaleido Biosciences, Inc. CIN: 47-3048279 , United States, Active	Jan 26, 2015	-	81 (As on Dec 31, 2020)	-

Kaleido Biosciences has raised a total funding of $165M over 3 rounds. Its latest funding round was a Series C round on Jun 25, 2018 for $*****. 5 investors participated in its latest round. Kaleido Biosciences has 8 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Kaleido Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 25, 2018	9180992	Series C	6683915	1984217	8967139	7923176
Jun 2017	5681662	Series B	2970429	3736423	Flagship Pioneering & 1 more	6602588

Access funding benchmarks and valuations. Sign up today!

View details of Kaleido Biosciences's funding rounds and investors

Kaleido Biosciences' employee count trend

Kaleido Biosciences has 9 employees as of Sep 26. Here is Kaleido Biosciences's employee count trend over the years:

Employee count trend for Kaleido Biosciences

Uncover Kaleido Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kaleido Biosciences include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Kaleido Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
7th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
979th	Kaleido Biosciences 2015, Cambridge (United States), Deadpooled	Developer of microbiome metabolic therapies for inflammatory conditions	$165M	ADIA, Fidelity Investments & 7 others	39/100